HLA Class I Ligandome Modulation by Zapnometinib and Influenza A Virus in Lung Cells

Immunopeptidomic analysis of HLA-I-presented peptides from human lung adenocarcinoma Calu-3 cells under two conditions: infection with Influenza A virus H3N2/Fukui and treatment with the MEK inhibitor zapnometinib. The dataset, shared by Hazem Hamza on figshare under CC-BY-4.0, reveals allotype-specific peptide abundance changes of 3–12% and significant modulation of 3–14% of ligands per condition. This work provides the first evidence of zapnometinib's impact on antigen presentation plasticity without substantially altering overall HLA-I surface expression.

Use Cases

• Analyzing condition-specific enrichment in cellular pathways like interferon-induced responses based on functional annotation results.
• Investigating allotype-specific changes in HLA-I-presented peptide relative abundance based on immunopeptidomic analyses.
• Studying ligandome remodeling effects on antiviral protein hubs like IFIH1, DHX58, and IFI16 during influenza infection.
• Comparing the immunomodulatory effects of MEK inhibition versus viral infection on peptide presentation pathways.

Strengths

• Dataset includes specific quantitative results, such as fold changes of 1.01-1.13 for HLA-I surface expression and log2 fold change ≥ 2 for modulated ligand subsets.
• Analysis is based on label-free LC–MS/MS and flow cytometry, indicating experimental rigor.
• License is clearly stated as CC-BY-4.0, facilitating open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is derived from a single cell line (Calu-3), which may limit generalizability.

Provenance

Source

figshare

Collection Method

Label-free LC–MS/MS analysis of HLA-I–presented peptides and flow cytometry quantification of surface HLA-I expression on human lung adenocarcinoma Calu-3 cells.

Freshness

Last updated 2026-05-26 06:02:12; freshness should be verified.